This article was written by

Follow

Analyst’s Disclosure: I/we have a beneficial long position in the shares of NVDA, MSCI, WING, ROL, INTU, ZTS, MA, KLAC, BR, ODFL, MSFT, DPZ, APH, V, BMI, COST, MPWR, LLY, CTAS, MRSH, ACN, TJX, MCO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

This article was written by

Follow

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Disclaimer: The contents of this article, my previous articles, and my comments are for informational purposes only and may not be considered investment and/or tax advice. I am a private investor from Europe and share my investing journey here on Seeking Alpha. I am neither a licensed investment advisor nor a licensed tax advisor. Furthermore, I am not an expert on taxes and related laws—neither in relation to the U.S. nor other geographies/jurisdictions. It is not my intention to give financial and/or tax advice, and I am in no way qualified to do so. Although I do my best to make sure that what I write is accurate and well-researched, I cannot be held responsible and accept no liability whatsoever for any errors, omissions, or consequences resulting from the enclosed information. The writing reflects my personal opinion at the time of writing. If you intend to invest in the stocks or other investment vehicles mentioned in this article—or in any investment vehicle generally—please consult your licensed investment advisor. If uncertain about tax-related implications, please consult your licensed tax advisor.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

I am an independent investor with more than 15 years of experience researching public companies, with a primary focus on identifying misunderstood businesses where the market’s short-term narrative differs from long-term fundamentals. Before concentrating on biotechnology, I was a long-term investor in Advanced Micro Devices (NASDAQ: AMD) during its multi-year turnaround and Maxar Technologies (NYSE: MAXR) prior to its acquisition. Those investments reinforced my conviction that meaningful returns often come from understanding the underlying business, competitive positioning, and long-term catalysts rather than reacting to short-term market sentiment. Over the past seven years, my research has become increasingly focused on small- and micro-cap biotechnology companies, particularly those developing novel therapies for oncology and hematologic malignancies. My investment process centers on fundamental research, including SEC filings, ClinicalTrials.gov records, FDA regulatory pathways, peer-reviewed scientific literature, conference presentations, and corporate communications. I also seek to understand clinical trial design, survival statistics, regulatory strategy, and the competitive landscape surrounding emerging therapies. One company I have followed extensively is SELLAS Life Sciences, where I have been a shareholder for more than seven years. My research has included reviewing publicly available regulatory filings, analyzing clinical trial developments, engaging with management through shareholder communications, and participating in discussions with independent AML specialists to better understand the evolving treatment landscape. While SELLAS has become one of my deepest research projects, my broader interests include immunotherapy, precision medicine, targeted oncology, and event-driven biotechnology investing. Professionally, I am the founder and owner of Mobilize Cloud, a digital consulting and software development firm based in Ohio. My career in technology has been built around solving complex problems, analyzing data, and developing practical solutions for businesses. Those same analytical skills have naturally shaped my investment philosophy: question assumptions, rely on primary sources whenever possible, and distinguish evidence from narrative. I do not claim to predict clinical trial outcomes or possess information beyond what is publicly available. Instead, my goal is to synthesize complex scientific, regulatory, and financial information into clear, well-supported research that helps investors better understand both the opportunities and the risks associated with innovative biotechnology companies. Through my writing, I hope to encourage thoughtful, evidence-based discussion around biotechnology and other sectors where deep research can uncover opportunities that may not be fully reflected in prevailing market sentiment. Whether the topic is biotechnology, technology turnarounds, or other event-driven investments, my objective is to help readers evaluate the facts, challenge conventional assumptions, and make more informed investment decisions.

This article was written by

Follow

Analyst’s Disclosure: I/we have a beneficial long position in the shares of CPX:CA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I have also written some out of the money put options and I intend to write more put options.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

The Florida Department of Health in Miami-Dade County has confirmed a locally acquired case of dengue fever, issuing an advisory as officials begin coordinating surveillance, prevention and mosquito control efforts in South Florida.

According to the advisory, the confirmed case involved transmission of the virus within the local area, rather than a case in which someone contracted the disease while traveling abroad and later returned to Florida. Health officials have not disclosed the exact neighborhood or specific location where the local transmission likely occurred, though the department said it has begun coordinated surveillance, prevention and mosquito control efforts in the area in response to the confirmed case.

Dengue is a viral illness spread primarily through the bite of Aedes aegypti mosquitoes, though the related Aedes albopictus species can also transmit the virus and is present in Florida as well. The disease typically presents as a flu-like illness, with symptoms that can include fever, severe muscle aches, joint pain and, in some cases, a skin rash. Symptoms of dengue generally appear within 14 days of being bitten by an infected mosquito and typically last anywhere from four days to a week once they develop.

Dengue fever is not considered contagious between people under normal circumstances and is rarely fatal, though the illness can be severely uncomfortable, having earned the nickname “breakbone fever” in some medical literature because of the intensity of the muscle and joint pain it can cause. In more severe cases, the disease can also cause gastrointestinal symptoms such as vomiting and diarrhea, along with symptoms like eye pain and, in rare instances, bleeding complications.

Miami-Dade’s confirmed local case comes during what public health officials have identified as the most active period of the year for dengue transmission in Florida, driven by the combination of summer heat, humidity and standing water that creates favorable breeding conditions for Aedes mosquitoes. The Centers for Disease Control and Prevention has reported a significant national rise in dengue activity over the past year, with federal surveillance data showing a 359% increase in reported U.S. dengue activity compared with historical averages, even as the large majority of cases nationally continue to be linked to international travel rather than local transmission.

Florida has recorded locally acquired dengue cases every year in recent years, with the state reporting 62 locally acquired cases in 2025, spread across Brevard, Hillsborough, Miami-Dade and Pasco counties. Miami-Dade County alone accounted for 25 of those 2025 cases. In 2023, Florida recorded an even higher total of 154 locally acquired dengue cases, with Miami-Dade County responsible for 139 of them, reflecting the county’s position as one of the state’s most consistent hot spots for local dengue transmission given its dense population, tropical climate and extensive history of international travel connections. Separately, the Florida Department of Health in Hillsborough County reported the state’s first locally acquired dengue case of 2026 in that county earlier this summer.

Currently, no dengue vaccine is approved for use among the general adult population in the United States. The one FDA-approved vaccine, Dengvaxia, is authorized only for children ages 9 to 16 who have laboratory-confirmed evidence of a prior dengue infection and who live in dengue-endemic U.S. territories such as Puerto Rico, and its manufacturer has announced plans to discontinue production of the vaccine in 2026. For the vast majority of Florida residents and mainland U.S. travelers, preventing dengue infection depends entirely on avoiding mosquito bites in the first place, since no widely available vaccine or specific antiviral treatment currently exists for the general population.

Public health officials have outlined several practical steps residents can take to reduce their risk of exposure to dengue-carrying mosquitoes. Using insect repellent registered with the Environmental Protection Agency remains one of the most effective preventive measures, alongside wearing long sleeves and pants during outdoor activities, particularly during the daytime hours when Aedes mosquitoes, unlike many other mosquito species, are most actively biting. Eliminating any standing water around homes and properties is also considered essential, since Aedes mosquitoes require only small amounts of stagnant water, such as that collecting in flowerpots, discarded containers, clogged gutters or unused tires, to breed successfully.

Miami-Dade has faced elevated mosquito-borne illness activity beyond dengue in recent months as well. The county confirmed its first locally acquired case of chikungunya, another mosquito-borne viral illness, in December, and the broader South Florida region has continued monitoring for both diseases throughout 2026 given the area’s consistent risk profile for Aedes-transmitted infections. Chikungunya, like dengue, is transmitted primarily by Aedes mosquitoes and causes symptoms including high fever and often debilitating joint pain, typically appearing within three to seven days of a bite from an infected mosquito.

With Florida now entering the height of its summer mosquito season, health officials in Miami-Dade and across the state are expected to continue closely monitoring both human case counts and mosquito surveillance data throughout the coming months, using that information to guide targeted mosquito control efforts and public health messaging in areas where infected mosquito populations or additional human cases are identified.

Three people were killed and at least seven others were wounded in a shooting Saturday afternoon at an In-N-Out restaurant in Twin Falls, Idaho, local authorities said, with police confirming the suspected shooter was found dead at the scene.

The shooting unfolded before 2:30 p.m. local time at the restaurant, located within a shopping center in the southern Idaho city. Social media video obtained by CBS News showed people fleeing the shopping center’s parking lot as multiple gunshots could be heard, with one clip showing a person carrying what appeared to be a firearm outside the restaurant before opening the doors of a parked sedan.

Twin Falls Police Chief Matthew Hicks confirmed during a news conference Saturday night that fatalities had occurred but said he could not immediately confirm an exact death toll. Joshua Palmer, a Twin Falls city spokesperson, initially told CBS News that at least three people had been killed and two others wounded, before later telling the Associated Press that the number of people injured had risen to at least seven.

Hicks said a number of people injured in the shooting were being treated at St. Luke’s Magic Valley Medical Center, a local hospital. The hospital posted a message to its own social media account urging the public to stay away from the facility unless facing a separate emergency. “Due to the active shooter incident occurring in Twin Falls, please avoid going to St. Luke’s Magic Valley unless it is an emergency,” the hospital wrote.

Hicks confirmed that the suspected gunman was dead but did not provide details on how the person died. “The suspected shooter in this incident is deceased,” Hicks said. “He was nearby on the scene there, and we are working to try to ascertain his identity and the motivations behind that.” As of Saturday night, authorities had not released the identity of the suspected shooter or any information about a possible motive.

Twin Falls resident Haley Dodaro, 43, described witnessing the chaos unfold while she and her mother were at the restaurant for lunch. Dodaro told the Associated Press that while the pair was waiting in the drive-thru line, they saw people running across the road and restaurant employees fleeing the building. She said she initially suspected a fire might have broken out, until a man directing traffic in a reflective vest told her there was an active shooter nearby. “So that’s when we knew there was a shooting,” Dodaro said in a text message to the AP. “People were running out crying and screaming. It was very scary.”

Hicks said investigators were working to interview a large number of witnesses who had been in the vicinity of the restaurant at the time of the shooting. “We have literally hundreds of people that were in some way, shape or form in the area of this restaurant at the time that are being interviewed right now,” Hicks said, underscoring the scale of the response and investigation underway in the shooting’s immediate aftermath.

Police shut down surrounding roads and a nearby bridge during the response to the shooting and asked residents in the area to stay away while officers worked the scene. An FBI spokesperson confirmed to CBS News that bureau agents were on site assisting local authorities with the investigation.

Twin Falls is located in southern Idaho, roughly 120 miles southeast of Boise. The city, home to a population of roughly 50,000 people, is known regionally as a commercial hub for south-central Idaho.

The shooting adds to a string of mass-casualty shootings that have drawn national attention in recent months, with local and federal law enforcement continuing to investigate the circumstances and motive behind Saturday’s attack. As of Saturday night, officials had not released additional details about the specific sequence of events inside or around the restaurant, nor had they confirmed the exact number of people killed beyond the initial reports of three fatalities.

Authorities said the investigation into the shooting remains active and ongoing, with police continuing to process the scene and interview witnesses well into Saturday night. No additional public updates on the identities of the victims or the suspected shooter had been released as of early Sunday morning.

Given the scale and violence of Saturday’s shooting, this is a distressing story for many readers, particularly those with connections to the Twin Falls community or who may have been near the restaurant at the time. Anyone personally affected by the shooting who is experiencing distress is encouraged to reach out to local crisis or mental health resources, and Idaho residents seeking immediate support can contact the 988 Suicide and Crisis Lifeline by calling or texting 988.

Elon Musk has jokingly referred to himself as a “former trillionaire,” poking fun at a dramatic decline in his estimated net worth following sharp valuation drops in both Tesla and SpaceX, a remark that has reignited broader discussion about the nature and volatility of billionaire wealth.

Musk made the comment in a post on X on July 24, writing “(Former) Trillionaire,” in an apparent reference to the extraordinary reversal in his fortune since briefly becoming the world’s first trillionaire following SpaceX’s blockbuster stock market debut in June. At its peak, Musk’s estimated net worth reached roughly $1.45 trillion, according to tracking from outlets including Forbes and Bloomberg. His fortune has since fallen to approximately $695.7 billion, according to Forbes, marking a decline of roughly $750 billion from that June peak.

The joke is notable in part because Musk has never officially sustained trillionaire status for an extended period; his brief crossing of the $1 trillion threshold came almost entirely as a result of SpaceX’s initial public offering. SpaceX shares priced at $135 in the IPO and initially surged as high as $225.64 before reversing sharply. As of late July, the stock had fallen roughly 50% from that all-time high, trading around $109 to $112. SpaceX’s decline has been driven by several factors, including two delayed Starship test launches, a $60 billion all-stock acquisition of AI coding company Cursor that diluted existing shareholders ahead of an August 6 lockup expiration, and a valuation that analysts say leaves little room for error. Starship’s 13th test flight succeeded on July 25, but the stock hit a new low regardless.

Tesla shares have also weighed heavily on Musk’s overall fortune, falling roughly 25% over the past month as of late July. The stock erased a full year of gains in a single session earlier in the summer, when shares fell 18% after Tesla reported second-quarter operating profit of $400 million, well below Wall Street’s expectations of $1.72 billion. Roughly $116 billion of the overall decline in Musk’s estimated net worth stems from a separate adjustment, after Forbes removed certain Tesla stock options from its calculation based on new vesting conditions Musk agreed to with the automaker.

Despite the scale of the paper losses, Musk remains by far the wealthiest person in the world, ranking well ahead of Google co-founders Larry Page, whose net worth is estimated at roughly $268.5 billion, and Sergey Brin, estimated at roughly $270.6 billion, as well as Amazon founder Jeff Bezos, estimated at roughly $252.6 billion.

Musk’s comment also carried a note of irony given remarks he made just weeks earlier. Around the time of SpaceX’s IPO, Musk told XPRIZE founder Peter Diamandis that “money will stop being relevant at some point in the future,” arguing that once artificial intelligence and robots begin producing more goods and services than the money supply can account for, currency will lose much of its practical purpose. Diamandis noted the irony of that statement at the time, given that Musk had just become the world’s first trillionaire.

Financial experts generally describe the kind of decline Musk has experienced as a “paper loss,” reflecting a change in the market valuation of assets rather than any actual cash leaving his accounts. Because the overwhelming majority of Musk’s wealth is tied to his ownership stakes in companies including Tesla, SpaceX, xAI, Neuralink and X, rather than cash or other liquid holdings, his estimated net worth can swing by tens of billions of dollars in a single trading session without him selling a single share. When Tesla or SpaceX shares fall, his estimated wealth falls in proportion; when the shares recover, the estimated wealth reappears in the same way. Unless the underlying shares are actually sold, any gains or losses remain unrealized on paper.

Dramatic swings in Musk’s fortune are not unprecedented. His net worth jumped by more than $60 billion in a single day on June 29, and he added another roughly $30 billion on Oct. 24 after Tesla reported stronger-than-expected results, illustrating how quickly his estimated wealth can move in either direction depending on market sentiment toward his companies.

Despite the recent decline, SpaceX remains widely viewed by analysts as one of the strongest assets in Musk’s business portfolio. The company continues to dominate the commercial rocket launch market, operates the rapidly expanding Starlink satellite internet network, and holds major contracts with NASA and the U.S. government. Even so, some Wall Street analysts have expressed caution about the company’s near-term trajectory. Morgan Stanley analysts wrote in late July that if SpaceX shares fell below $100, it would imply that investors see no meaningful value in the company’s artificial intelligence-related business, with some analysts already assigning “zero or negative value” to that segment given the company’s accelerating spending on space and connectivity infrastructure and what the analysts described as largely uncertain economics.

Musk’s overall fortune has continued to reflect the broader volatility characteristic of modern billionaire wealth built primarily on technology company valuations rather than traditional industrial or cash-based assets. A single earnings report, product announcement or shift in investor sentiment can add or erase tens of billions of dollars from his estimated net worth within days, a dynamic that has repeated throughout 2025 and 2026 as Tesla and SpaceX shares have moved through several distinct cycles of sharp gains followed by steep pullbacks.